Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its President and CEO, Myron Holubiak, participated in a Benzinga interview discussing the company's product pipeline, Covid-19 impact, and future milestones. The company focuses on critical care products, particularly in anti-infective treatments and stem cell therapy. Notably, its lead product, Mino-Lok®, is in a Phase III trial and has received Fast Track designation by the FDA. The interview is available on the Citius corporate website.
- Mino-Lok® is currently in a Phase III pivotal superiority trial.
- Mino-Lok® has received Fast Track designation from the FDA.
- The company's focus on critical care and anti-infective products positions it well in the market.
- Risks associated with clinical trials could impact product development.
- The ongoing Covid-19 pandemic may affect operations and clinical trials.
CRANFORD, N.J., April 22, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Citius President and CEO, Myron Holubiak, was featured in an interview with Benzinga discussing the Company's product pipeline, the impact of Covid-19, and upcoming milestones.
The full video interview can be viewed on the Citius corporate website here.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase III pivotal superiority trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Safe Harbor
This press release and the interview to which it relates may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates, including Mino-Lok®; our ability to enroll patients in our clinical trials, risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the impact of Covid-19 on our employees, operations, clinical trials, or product candidates; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein or therein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Relations for Citius Pharmaceuticals:
Andrew Scott
Vice President, Special Projects
T: 908-967-6677 x105
E: ascott@citiuspharma.com
Ilanit Allen
T: 908-967-6677 x113
E: iallen@citiuspharma.com
View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-ceo-myron-holubiak-featured-in-benzinga-interview-301274946.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What is the significance of Mino-Lok® for Citius Pharmaceuticals?
What recent developments did Citius Pharmaceuticals announce?
What is the current status of Citius Pharmaceuticals' clinical trials?
How has Covid-19 impacted Citius Pharmaceuticals?
What does Fast Track designation mean for Citius Pharmaceuticals?
